Compare IDT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | VOR |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 1996 | 2021 |
| Metric | IDT | VOR |
|---|---|---|
| Price | $80.37 | $18.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $39.00 |
| AVG Volume (30 Days) | 207.5K | ★ 1.1M |
| Earning Date | 09-28-2026 | 11-12-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ 14.95 | N/A |
| EPS | ★ 3.46 | N/A |
| Revenue | ★ $1,231,495,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.98 | ★ N/A |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $45.72 | $6.50 |
| 52 Week High | $77.28 | $39.49 |
| Indicator | IDT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 81.25 | 36.87 |
| Support Level | $47.72 | $11.62 |
| Resistance Level | N/A | $19.70 |
| Average True Range (ATR) | 2.60 | 1.23 |
| MACD | 1.11 | -0.37 |
| Stochastic Oscillator | 96.21 | 23.02 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.